Sichuan Hebang Biotechnology Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Sichuan Hebang Biotechnology.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Chemicals earnings growth | 39.5% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
Is Sichuan Hebang Biotechnology (SHSE:603077) A Risky Investment?
Nov 19
Returns On Capital At Sichuan Hebang Biotechnology (SHSE:603077) Have Stalled
Sep 25Sichuan Hebang Biotechnology Corporation Limited's (SHSE:603077) Shares Not Telling The Full Story
Aug 16Return Trends At Sichuan Hebang Biotechnology (SHSE:603077) Aren't Appealing
Jun 04Investors Holding Back On Sichuan Hebang Biotechnology Corporation Limited (SHSE:603077)
May 13Is Sichuan Hebang Biotechnology (SHSE:603077) A Risky Investment?
Mar 07Here's Why I Think Sichuan Hebang Biotechnology (SHSE:603077) Is An Interesting Stock
Apr 21In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sichuan Hebang Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2024 | 9,203 | 486 | -933 | -205 | N/A |
| 6/30/2024 | 9,582 | 859 | -1,159 | -362 | N/A |
| 3/31/2024 | 8,429 | 916 | -1,572 | -700 | N/A |
| 12/31/2023 | 8,824 | 1,283 | -748 | 80 | N/A |
| 9/30/2023 | 8,980 | 1,398 | 272 | 886 | N/A |
| 6/30/2023 | 9,651 | 1,789 | 575 | 1,246 | N/A |
| 3/31/2023 | 12,347 | 3,161 | 1,541 | 2,383 | N/A |
| 12/31/2022 | 13,039 | 3,807 | 1,708 | 2,644 | N/A |
| 9/30/2022 | 13,353 | 4,438 | 773 | 2,970 | N/A |
| 6/30/2022 | 13,517 | 4,741 | 1,682 | 3,670 | N/A |
| 3/31/2022 | 11,409 | 3,815 | 1,535 | 3,537 | N/A |
| 12/31/2021 | 9,987 | 3,018 | 1,462 | 3,271 | N/A |
| 9/30/2021 | 8,494 | 2,248 | 1,975 | 2,627 | N/A |
| 6/30/2021 | 6,768 | 908 | 1,276 | 1,829 | N/A |
| 3/31/2021 | 5,902 | 319 | 685 | 843 | N/A |
| 12/31/2020 | 5,261 | 41 | 172 | 369 | N/A |
| 9/30/2020 | 5,115 | -147 | -307 | 79 | N/A |
| 6/30/2020 | 5,351 | 264 | -572 | 13 | N/A |
| 3/31/2020 | 5,565 | 372 | -668 | 11 | N/A |
| 12/31/2019 | 5,969 | 517 | -500 | 163 | N/A |
| 9/30/2019 | 6,200 | 380 | -243 | 378 | N/A |
| 6/30/2019 | 6,154 | 387 | 40 | 488 | N/A |
| 3/31/2019 | 6,285 | 426 | 537 | 954 | N/A |
| 12/31/2018 | 6,009 | 363 | 581 | 944 | N/A |
| 9/30/2018 | 5,990 | 622 | 574 | 967 | N/A |
| 6/30/2018 | 5,625 | 535 | N/A | 1,005 | N/A |
| 3/31/2018 | 4,961 | 395 | N/A | 378 | N/A |
| 12/31/2017 | 4,738 | 518 | N/A | 177 | N/A |
| 9/30/2017 | 4,400 | 477 | N/A | 189 | N/A |
| 6/30/2017 | 4,041 | 451 | N/A | 247 | N/A |
| 3/31/2017 | 3,722 | 436 | N/A | 270 | N/A |
| 12/31/2016 | 3,463 | 318 | N/A | 575 | N/A |
| 9/30/2016 | 3,206 | 260 | N/A | 558 | N/A |
| 6/30/2016 | 2,954 | 226 | N/A | 248 | N/A |
| 3/31/2016 | 3,043 | 255 | N/A | 548 | N/A |
| 12/31/2015 | 2,863 | 240 | N/A | 449 | N/A |
| 9/30/2015 | 2,757 | 144 | N/A | 173 | N/A |
| 6/30/2015 | 2,628 | 135 | N/A | 325 | N/A |
| 3/31/2015 | 2,282 | 679 | N/A | -9 | N/A |
| 12/31/2014 | 2,186 | 672 | N/A | 205 | N/A |
| 9/30/2014 | 1,979 | 715 | N/A | -20 | N/A |
| 6/30/2014 | 1,871 | 696 | N/A | -172 | N/A |
| 3/31/2014 | 1,660 | 54 | N/A | -121 | N/A |
| 12/31/2013 | 1,603 | 64 | N/A | -407 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 603077's forecast earnings growth is above the savings rate (2.8%).
Earnings vs Market: Insufficient data to determine if 603077's earnings are forecast to grow faster than the CN market
High Growth Earnings: Insufficient data to determine if 603077's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 603077's revenue is forecast to grow faster than the CN market.
High Growth Revenue: Insufficient data to determine if 603077's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 603077's Return on Equity is forecast to be high in 3 years time